Dr. Rubinson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Avenue
Boston, MA 02215Phone+1 617-632-4405Fax+1 617-632-5370
Summary
- I am a board certified medical oncologist specializing in gastrointestinal malignancies.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2014- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2013
- Brigham and Women's HospitalResidency, Internal Medicine, 2007 - 2010
- Brigham and Women's HospitalInternship, Internal Medicine, 2007 - 2008
Harvard Medical SchoolClass of 2007
Certifications & Licensure
MA State Medical License 2009 - 2026
ME State Medical License 2023 - 2026
VT State Medical License 2022 - 2026
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsBlockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.Paul E Oberstein, Andressa Dias Costa, Emily A Kawaler, Victoire Cardot-Ruffino, Osama E Rahma
Cancer Immunology Research. 2024-09-03 - 1 citationsClinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ g...Harshabad Singh, Kristen E Lowder, Kevin Kapner, Ronan J Kelly, Hui Zheng
Nature Communications. 2024-08-09 - 2 citationsDesign and Implementation of an Opt-Out, End-to-End, PreemptiveTesting Program for Patients Planned for a Systemic Fluoropyrimidine.Joseph O Jacobson, Garrett Rompelman, Angela Chen, Samantha Morrison-Ma, Lindsay Murray
JCO Oncology Practice. 2024-08-01
Journal Articles
- Diabetes, Weight Change, and Pancreatic Cancer RiskDouglas A Rubinson, Kimmie Ng, Meir J Stampfer, Brian M Wolpin, JAMA Oncology
- Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic CancerRichard F Dunne, Leona A Doyle, William C Hahn, Jason L Hornick, Andrea J Bullock, Sapna Syngal, Albert C Koong, Natalia Khalaf, Brian M Wolpin, Douglas A Rubinson, Da..., Nature
Authored Content
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Join now to see all
Press Mentions
A Closed-Loop Drug-Delivery System Could Improve ChemotherapyApril 25th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
